Provided is the use of eteplirsen for the manufacture of a medicament for the treatment of Duchenne muscular dystrophy (DMD) in a patient who has a mutation of the DMD gene that is amenable to exon 51 skipping, wherein the medicament is adapted to be administrable intravenously to the patient at a dose of about 30 mg/kg weekly for more than 120 weeks.
